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1. Introduction
Hematopoietic stem cell transplantation (HSCT) is an established treatment modality with a
curative potential in a variety of hematological disorders. Although remarkable advances in
transplant immunology and supportive care allowed widespread use of HSCT, transplant
related morbidity and mortality remain as a problem [1-7]. Early complications including si‐
nusoidal obstruction syndrome (SOS), hemorrhagic cystitis, engraftment syndrome, idio‐
pathic pneumonia syndrome (IPS), infections and graft versus host disease (GVHD) are the
major causes of morbidity and non relapse mortality (NRM). High doses of radiotherapy
and chemotherapy of the conditioning regimen have adverse effects on all organs and tis‐
sues of the recipient, which also triggers several early and late effects of variable intensity [1,
3, 5-8]. Iron overload (IO) is a relatively common condition in patients with hematological
malignacies and HSCT recipients. Free iron which accompanies IO might contribute to the
already existing prooxidant state in HSCT recipients by inducing the formation of reactive
oxygen species (ROS). Tissue peroxidation and organ damage, as a consequence, contribute
to the development of some early transplant complications [2, 4, 5, 9]. Increasing number of
transplants performed each year and improved transplant techniques result in a rise in the
number of long term survivors. The primary goal of HSCT is to cure the primary disease.
However long term transplant related morbidity might be very challenging and might sig‐
nificantly impair the quality of life. Late effects might be the consequence of the direct toxici‐
ty of chemoradiotherapy and/or the immunologic complications mainly consisting of
GVHD. Besides the secondary late effects including osteoporosis and dental caries, very late
effects, namely cardiovascular toxicity considered as tertiary late effect may also occur.
Among this wide spectrum of complications, IO has a substantial role as a contributor to liv‐
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er toxicity, infections and SOS and as a predictor of transplant outcome. Hematopoietic SCT
recipients have been demonstrated to have a high degree of liver iron content (LIC) almost
in the range of hereditary hemochromatosis (HH) and IO was shown to cause liver fibrosis,
heart failure, hypogonadism, diabetes and endocrinopathy in HSCT recipients in the long
run [4, 6, 7, 10]. 
Iron is an essential element which plays a key role in several biochemical reactions including
oxygen transport and electron transfer. It mediates the conversion of hydrogen peroxyde
(H2O2) to highly toxic free radicals leading to tissue damage by oxidation of proteins, per‐
oxidation of membrane lipids and modification of nucleic acids [4]. Under normal circum‐
stances, an appreciable concentration of free iron does not exist outside physiological sinks.
Any released ferrous iron (Fe+2) is immediately chelated in cells by compounds such as cit‐
rate or adenosine diphosphate. Thus, labile iron could not participate in the Haber–Weiss
reaction, which catalyses the formation of ROS. Free iron may directly initiate lipid peroxi‐
dation which destroys membrane structure resulting in increased oxidative stress and cellu‐
lar damage. Excess iron accumulation causes chronic free radical induced tissue damage in
multiple organs and leads to progressive organ dysfunction, which results in significant
morbidity and mortality. In this respect, IO should be prevented in order to preclude the ad‐
verse impact of free iron on natural homeostasis [9, 11].
This chapter will focus on iron balance and the course of excess iron in HSCT recipients. The ad‐
verse impact of IO on transplant outcome and the preventive strategies will also be discussed.
2. Body
2.1. Iron homeostasis
Iron is vital for all living organisms and takes part in several metabolic processes, including
DNA synthesis, oxygen and electron transport. Although iron is a critical element in cell
growth and multiplication, it is potentially toxic in excess amounts by generating ROS [5,
11-13]. Reactive oxygen species have a potential to damage DNA and proteins by lipid per‐
oxidation. Labile iron participates in free radical formation via Fenton reaction which was
first recognized in 1894. Namely, trace amounts of iron as Fe+2 could catalyze the oxidation
of tartrate by H2O2. Consequently, superoxide anion (O2-) or H2O2 is converted to toxic free
radicals such as hydroxyl radical (OH-). This process is mediated by the Fenton reaction cat‐
alyzed by iron, where O2- reduces ferric iron (Fe+3) to produce oxygen and Fe+2. This reduced
iron becomes reoxidized by H2O2 to produce OH- [5, 11].
Figure 1. a. Fenton reaction; b. Iron catalyzed Haber–Weiss reaction or the superoxide driven Fenton reaction [5].
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There are no physiological mechanisms in humans to excrete excess iron and iron homeosta‐
sis is primarily regulated at the level of absorbtion [4, 9, 11, 14-16]. The majority of iron ab‐
sorbtion occurs via enterocytes in the proximal small intestine. The conversion of dietary
inorganic non–heme iron to Fe+2 is facilitated by the brush border ferri reductases. Iron is
transported across the cellular membrane by the divalent metal transporter 1 (DMT1) which
transfers Fe+2 across the apical membrane and into the cell through a proton coupled process
[9, 15, 16]. Ferroportin is an iron efflux pump that mediates the export of Fe+3 from the enter‐
ocyte. Prior to transport, Fe+2 is converted to Fe+3 by either hephaestin or ceruloplasmin both
of which have ferroxidase activity. Subsequently, iron is uploaded to transferrin which is the
primary iron transporter in the circulation. Ferric iron bound to transferrin is soluble and
non reactive. The majority of iron (60–70%) is incorporated into hemoglobin while the rest is
stored in hepatocytes, myoglobin and reticuloendothelial macrophages [9]. Hepcidin, the
main regulator of iron absorbtion, inhibits intestinal absorbtion and release of storage iron in
iron-overloaded states, whereas its expression is markedly decreased in iron deficiency
states. Hepcidin interacts directly with ferroportin, causing its internalization, degradation
and blocking iron release from cells to plasma. Hepcidin acts as an acute phase reactant
which is responsible for the anemia of inflammation. Its production is upregulated by body
iron excess and inflammation whereas downregulated by anemia and hypoxia [9, 14, 16].
Cell survival depends on the balance between the destructive and beneficial effects of iron
[9, 12]. Natural iron homeostasis comprises regulation mechanisms to control iron excess.
The primary protective pathway is the sequestration of iron in ferritin or transferrin. Ferritin
is the chief storage molecule while transferrin is functionary for the transport of iron. Ferri‐
tin captures and buffers the intracellular iron pool, thus it makes iron available for critical
cellular processes while protecting lipids, DNA and proteins from potentially toxic effects of
iron. Iron stored in ferritin is not capable of catalyzing radical reactions and is considered as
safe. It is well known that serum ferritin concentration closely parallels body iron reserves.
However, as free iron is the main form of iron which can precipitate in oxidative stress, any
measure of unbound iron will result in deleterious effects. The balance of free iron to bound
iron changes and free iron becomes available to catalyze free radical reactions in iron over‐
loaded states [5, 9]. Large amounts of excess iron in the circulation are likely to exceed the
serum iron binding capacity (SIBC) and non transferrin bound iron (NTBI) will emerge
eventually. Non transferrin bound iron bypasses the normal regulatory mechanism of recep‐
tor mediated iron uptake and is able to stimulate the peroxidation of membrane lipids and
the formation of ROS. The intracellular counterpart of NTBI is considered as labile iron pool
(LIP) which is bound mainly to low molecular weight compounds. Labile iron pool is cata‐
lytically active and capable of initiating free radical reactions. The expansion of the LIP and
simultaneously increased NTBI may trigger cell toxicity. Generation of LIP leads to unregu‐
lated iron uptake and subsequent intracellular storage either within ferritin molecules or as
hemosiderin. The adverse effects of IO can arise from the elevation of NTBI and LIP in plas‐
ma and might as well cause organ damage mediated by the accumulation of tissue iron in
target organs. The equilibrium between the LIP and iron locked in the ferritin shell is critical
to maintain the normal function of cellular iron enzymes. Imbalance in this equilibrium re‐
sults in the uncontrolled loading of organs, such as the liver, heart and endocrine glands,
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with free iron which generates free radicals and causes cell damage [12, 17]. Eventually,
NTBI and LIP may be more relevant iron markers than serum ferritin and transferrin as a
predictor of IO induced tissue damage. Alterations in ferritin levels are seen commonly in
clinical practice often reflecting perturbations in iron homeostasis or metabolism. Serum fer‐
ritin differs markedly from tissue ferritin in molecular weight, iron and carbonhydrate con‐
tent, subunit size and amino acid sequence. The extracellular form of ferritin, termed as
serum ferritin, is used as a clinical marker of iron status. Tissue ferritin is the more efficient
storage form of iron than is serum ferritin and the function of serum ferritin has to be clari‐
fied in these circumstances [9, 12]. Serum ferritin is usually correlated with NTBI, whereas
inflammation, acute and chronic liver diseases and malignancies may also cause elevated se‐
rum ferritin levels regardless of the iron stores [12].
2.2. Iron overload and stem cell transplantation
Iron overload is a significant problem in autologous (auto) and allogeneic (allo) HSCT recip‐
ients and may adversely affect transplant outcome [4, 18]. The diagnosis of IO has been re‐
ported in up to 88% of long term survivors of HSCT on the basis of serum ferritin levels [19].
Iron overloaded state may last for a long time after transplantation. In a cross sectional
study by Majhail et al, in which LIC on MRI was used for diagnosis, the prevalence of IO
was reported to be 32% in allo-HSCT recipients who had survived 1 year or more following
HSCT [20]. In another study by the same group, serum ferritin levels were found to be
above 1000 ng/ml in 34% of allo-HSCT and 13% of auto-HSCT recipients. Thus, IO may be
less prevalent among recipients of auto-HSCT compared to allo-HSCT as expected [21].
The main causes of IO in HSCT are prolonged dyserythropoiesis, increased intestinal iron
absorbtion due to anemia and chemotherapy associated mucositis which leads to increased
iron absorbtion, transfusion burden and release of iron from injured tissues [8, 22].
Iron overload is particularly common in HSCT recipients with hemoglobinopathies and
hematological malignancies which require frequent transfusions and is associated with inef‐
fective erythropoesis such as acute leukemia and myelodysplastic syndrome (MDS). Trans‐
fusion load is considered to be the principal cause of IO in this group, as each unit of packed
red blood cells (PRBC) contains approximately 200–250 mg iron. Since there is no physiolog‐
ical mechanism for excreting excess iron, iron accumulation is inevitable after 10–20 transfu‐
sions [22-24]. Ineffective erythropoiesis might be a contributing factor leading to excessive
iron absorbtion particularly in MDS and thalassemia which is mediated by erythroid regula‐
tors of iron metabolism which suppress hepcidin and result in increased iron absorbtion.
Elevated growth differentiation factor 15 (GDF–15) levels are considered to be the initiating
event in this context. Ineffective erythropoiesis either as a feature of the underlying disease
or a consequence of intensive treatment leads to inhibition of hepcidin possibly due to over‐
expression of GDF–15 and thus increases iron absorbtion and toxicity. Hematopoietic SCT
recipients are at risk of IO due to prior transfusion load, increased iron absorbtion related to
elevated GDF–15 levels and peri–tansplant transfusions [22, 24, 25].
Bone marrow (BM) and tumor cell destruction which occurs as a consequence of high dose
therapy and release of iron from damaged cells as well as underutilization of iron due to the
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inhibition of erythropoiesis as a result of cytotoxic therapy are important factors in the etiol‐
ogy of IO. Erythropoiesis, which is the main route of iron utilization, is temporarily halted
by the conditioning regimen [8, 22, 23, 26]. Conditioning treatment with chemo/radiothera‐
py during HSCT causes toxicity and immunosuppression leading to organ damage and in‐
fectious complications mainly in the first 3 months of the procedure [27]. Free iron, which
acts as a free radical catalyser, might increase the toxicity of the conditioning regimen dur‐
ing HSCT. Serum iron parameters were demonstrated to be elevated 2–3 days during condi‐
tioning chemotherapy prior to stem cell infusion in a report by Gordon et al [13]. Non
transferrin bound iron appears shortly after conditioning regimen and remains detectable in
most patients throughout the peri–transplant period. Transferrin saturation (TS) increases
during the conditioning regimen, often reaching to levels above 80% with the consequent
emergence of NTBI [28]. The ability of ferritin to sequestrate iron and binding of iron to
transferrin is exhausted in HSCT recipients receiving conditioning regimen, thus leading to
excess NTBI formation. The extent of BM suppression caused by the conditioning regimen is
correlated with the elevation of NTBI [27]. A substantial decrease in plasma anti-oxidant de‐
fense has also been demonstrated in HSCT recipients, and NTBI levels were found to be in‐
versely correlated with plasma antioxidant capacity in a report by Yegin et al [29]. A
derangementof the prooxidative/antioxidative balance was demonstrated as antioxidants
only partially recover to baseline values until day 14 after HSCT [30, 31].
Hepatic toxicity due to chemotherapy and radiation might lead to hepatocellular damage
with subsequent further release of hepatic iron stores. Liver damage may also disturb trans‐
ferrin synthesis [28, 30]. A decrease in transferrin due to hepatic toxicity, stored iron leaking
from injured liver to blood and a suppression of erythropoietic activity during treatment
may causes elevated TS levels. Thus, increasing TS succeeds and contributes to the appear‐
ance of potentially toxic NTBI in the circulation. Iron in its NTBI form is a potent catalyst in
Fenton’s reaction which produces ROS capable of causing cellular damage through various
mechanisms. Tissue damage such as mucositis and liver injury is common after HSCT and
may be partly mediated by NTBI during cytotoxic chemoradiotherapy [28, 29, 32]. It is indi‐
cated that increased NTBI levels may contribute to organ toxicity and infectious complica‐
tions in the early post–transplant period [29].
Complication Incidence Mechanism of Injury
Infection Variable Immune dysregulation, mediated in part by IO, iron-rich
microbial environment
Chronic liver disease Common Multifactorial, including IO
SOS Common (up to 54%) Conditioning regimen, prior irradiation, possibly IO
IPS Uncommon (2-8%) Pro-inflammatory events and increased ROS (mediated by
IO)
Table 1. Complications of IO in patients undergoing HSCT [24]





Infections Mucormycosis, invasive aspergillosis, listeria monocytogenes and other
infections
Acute GVHD No clear evidence available, elevated ferritin might increase risk
SOS Iron overload might increase risk
NRM Elevated ferritin associated with increased risk in allo and auto-HSCT recipients
Late ("/>1 year)
Infections Mucormycosis, invasive aspergillosis and other infections
Chronic GVHD No clear evidence available, decreased risk reported with elevated ferritin
Liver Function Abnormalities Iron overload increases risk
Cardiac Late Effects Iron overload might increase risk
NRM No clear evidence available
Table 2. The Role of IO in Early and Late Complications of HSCT [4]
Iron toxicity may play an important role in the pathogenesis of transplant related complica‐
tions [Table 1, 2]. In a series of 25 patients who underwent HSCT, very high levels of ferritin
(>3000 ng/ml) and TS (>100%) dramatically increased transplant related mortality (TRM)
and decreased overall survival (OS) which was particularly attributed to infections [32]. As
iron is an essential element for all pathological microorganisms, excess amounts of free iron
might increase microbial growth and the probability of severe infections [33]. The coexis‐
tence of excess plasma iron with the damage to the mucosal barrier may also predispose to
infectious events with bacterial translocation. Hypoferraemia is a normal response to infec‐
tion and appears to be a part of a natural resistance mechanism whereas hyperferremia can
predispose to bacterial and fungal infections. In this context, elevated TS and ferritin levels
are proven risk factors for the development of systemic fungal infections in patients with
hematological malignancies [1, 33, 34]. Furthermore, an increase in late fungal infections, es‐
pecially mucormycosis, has been reported in iron loaded patients after HSCT [35]. Elevated
pre–transplant ferritin levels seem to effect prognosis adversely in myeloablative HSCT pri‐
marily due to increased NRM. On the other hand, elevated iron stores apart from providing
a milieu for infection and organ toxicity, may also be in relevance to tumor growth. Thus
elevated ferritin levels might be in association with relapse and relapse mortality [36]. Ma‐
hindra et al reported that elevated pre–transplant serum ferritin level was an independent
adverse risk factor for OS in patients undergoing non myeloablative HSCT. Inferior survival
in patients with elevated ferritin was related to both higher rates of treatment related mor‐
tality and relapse mortality [37]. On the other hand it should also be noted that ferritin is an
acute phase reactant and a marker of inflammation besides its role as a surrogate marker of
iron status. Thus, elevated ferritin levels might as well indicate a group of patients with
more agressive primary disease biology and a subgroup of patients who are already more
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likely to experience disease relapse. Thus the association of elevated ferritin levels with re‐
lapse might be unrelated to IO.
The adverse impact of IO on transplant outcome has been demonstrated most convincingly
in patients with thalassemia where class III patients with extensive liver damage had higher
TRM [38]. Besides increased TRM, other complications attributed to IO includes fungal in‐
fections, hepatic dysfunction and hepatic SOS/Veno occlusive disease (VOD) [4, 27, 38, 39].
In fact, thalassemia is a benign disorder and ferritin is directly a marker of excess iron and
elevated levels could not be attributed to the biology of an underlying malignant pathology.
As a result of the above mentioned data, pre–transplant serum ferritin was included in a
prognostic scoring system for acute leukemia and MDS patients undergoing allo–HSCT [40].
The late morbidity of IO is primarily due to the involvement of heart and liver. Although
iron related liver function test (LFT) abnormalities have been reported, there are no studies
that describe the role of IO in late onset cardiomyopathy and hepatic fibrosis/cirrhosis in pa‐
tients transplanted for diseases other than thalassemia. Post–transplant iron depletion thera‐
py has been shown to reverse hepatic fibrosis and cardiomyopathy in children with
thalassemia who have undergone allo–HSCT [4].
2.3. Iron overload and transplant complications
2.3.1. Liver complications
Liver disease is a frequent cause of morbidity and mortality following allo–HSCT and af‐
fects 90% of recipients and up to 5–10% of toxic deaths are liver related. Liver injury in the
early post–transplant period may be secondary to drug toxicity, SOS, acute GVHD, oppor‐
tunistic infections, total parenteral nutrition, tumor invasion and cholestatic disorders [3,
41]. Long term liver disease is also a common complication of HSCT, as 57, 5% of survivors
developed chronic liver disease (CLD) at 2 years after transplantation in a retrospective ser‐
ies of 106 patients reported by Tomas et al. In this retrospective study, the combination of
chronic hepatitis C and IO was presented as the most frequent cause of CLD [41]. On the
other hand, chronic GVHD also contributes to liver toxicity. The timing and pattern of LFT
abnormalities, history of pre or post transplantation hepatitis, presence of GVHD at other
sites and transfusion burden might be helpful in determining the etiology of liver disease.
Accurate diagnosis of the etiology of liver dysfunction is generally problematic even though
the patterns of biochemical, clinical and histological abnormalities can aid diagnosis. Liver
biopsy in patients following HSCT is not without risks, particularly due to thrombocytope‐
nia during the early post–transplant period. The most common indication for liver biopsy is
to assess the possibility of GVHD in allo–HSCT in the late post–transplant period with per‐
sistently abnormal LFTs and no evidence of GVHD on other sites. In this clinical setting, the
sensitivity and specifity of serum ferritin as a marker of IO is not well defined due to its con‐
comittant role as an acute phase reactant [3, 5, 8, 24, 41-43]. Liver biopsy may be performed
when atypical clinical features are present or multiple disease processes are likely to occur
simultaneously or when there is poor response to therapy that has been instituted [44]. The
management of liver dysfunction under these conditions may be complicated as overlap‐
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ping features often complicate the diagnosis and establishing the correct diagnosis is crucial
to institute disease specific therapy. Autopsies performed in 10 patients who died early after
HSCT showed iron accumulation in a range equivalent to that of patients suffering from HH
[26]. A cumulative cirrhosis incidence of 3, 8% by 20 years after HSCT has been reported
previously [8]. This rate seems to be an underestimation as the majority of long term survi‐
vors have not been subjected to liver biopsy. In a retrospective study by Sucak et al, severe
IO was demonstrated in 75% of 24 liver biopsies which were performed with the presump‐
tive diagnosis of hepatic GVHD in 20 patients with persistent elevation of liver enzymes in
the post–transplant setting. The initial clinical diagnosis of GVHD was refuted in 43, 5% of
the patients. Median number of post–transplant transfusions, TS and ferritin levels were
found to be significantly higher in patients who had histologically proven hepatic IO. A sig‐
nificant correlation between serum ferritin levels and histological grade of iron in the hepa‐
tocytes was also demonstrated [10]. In another study by Iqbal et al, the diagnosis obtained at
laparoscopic liver biopsies altered targeted therapy in 31% of patients. Iron overload was
found in 81, 25% of a total of 32 biopsies [45]. A diagnosis of IO after HSCT was demonstrat‐
ed based on histological evidence of siderosis found in 52, 4% of liver biopsies performed at
15–110 days post-transplant in another study. Liver biopsies were performed for diagnostic
purposes in patients with chronic liver dysfunction. An improvement in LFT was observed
in 21 of the 23 patients (91%) with IO who underwent phlebotomy [41]. Namely, IO seems to
be underestimated as a cause of liver dysfunction in HSCT setting and liver biopsy which
allows disease specific therapy could be life saving.
Hepatic IO may also worsen the natural course of chronic viral hepatitis and the response to
antiviral therapy. Fujita et al demonstrated that liver iron deposition was more common in
chronic hepatitis C compared to hepatitis B and was associated with liver disease progres‐
sion. Increased hepatic iron stores in chronic hepatitis C were related to resistance to Inter‐
feron/Ribavirin treatment [46]. Thalassemic patients with liver fibrosis and hepatomegaly
who undergo HSCT, have a markedly reduced OS and event free survival compared to pa‐
tients without evidence of liver disease. The liver disease in these patients is due to a combi‐
nation of severe IO and chronic viral hepatitis both of which improve with effective iron
chelation therapy [19, 26, 47]. Iron is also deposited in other tissues such as myocardium or
BM. Slow and spontaneous decrease in iron stores has been reported in thalassemic children
in the years following HSCT. This natural iron depletion could normalize iron stores in indi‐
viduals with mild siderosis. However, in patients with moderate to severe IO this slow de‐
pletion could not prevent the development of liver dysfunction. For this reason, iron
depletion protocols have been developed for patients with severe IO [19, 23, 26, 47].
2.3.2. Sinusoidal obstruction syndrome (veno occlusive disease)
Sinosoidal obstruction syndrome is a treatment related toxicity associated with auto and al‐
lo–HSCT which is seen in 6–54 % of the recipients. The severity of SOS ranges from a mild
reversible to a progressive course with a mortality rate close to 100% [5, 24].
The role of pre–transplant hyperferritinemia in the development of SOS was first demon‐
strated  by  Morado  et  al  in  a  cohort  of  180  auto–HSCT  recipients.  In  this  prospective
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study, SOS was defined in 12, 2% of patients based on McDonald criteria.  Patients with
pre–transplant ferritin levels above 300 mg/dl were shown to have a higher risk of devel‐
oping SOS [48]. In a recent report by Maradei et al, a pre–transplant serum ferritin level
above  1000  ng/dl  was  identified  as  an  independent  risk  factor  for  the  development  of
SOS [39]. A retrospective study of 250 HSCT recipients by Sucak et al, in which SOS in‐
cidence was reported to be 29,  7%,  demonstrated significantly higher  pre–transplant  se‐
rum ferritin  levels  in  patients  with SOS [49].  In  another  study reported by Sucak et  al,
pre–transplant ferritin levels were found to be higher in HSCT recipients who developed
SOS  in  the  post–transplant  setting  [50].  Serum  ferritin  may  be  increased  in  conditions
other than IO in this particular group of patients, including chronic inflammation and in‐
fection.  Nevertheless,  values  higher  than  1000  ng/ml  were  rarely  reported  in  these  in‐
flammatory conditions [1, 25, 29, 39, 48-51].
Iron induced hepatotoxicity is multifactorial which involves oxidative stress and modula‐
tion of gene expression of Kuppfer cells. Cellular injury is induced by iron generated ROS
and peroxidation of lipid membranes [39]. Risk factors associated with the development of
SOS are defined as preexisting liver dysfunction, previous abdominal irradiation, high dose
total body irradiation, high dose preperative regimens, advanced disease and HLA mis‐
match or unrelated HSCT. The typical hepatocellular lesion of SOS mainly occurs in zone 3
of hepatic acines including a characteristic endothelial lesion which is shown to be associat‐
ed with hypercoagulability. The oxidant effect of iron on endothelial and and hepatocyte
membranes mediated by ROS contributes to the development of these typical lesions of SOS
[48, 50]. The risk of SOS is higher in carriers of at least one allele of the hemochromatosis
gene, HFE, which predisposes to iron deposition in the liver [24].
2.3.3. Infections
Patients with HH and other diseases with IO are considered to be more susceptible to infec‐
tions, as iron adversely affects the phagocytic, chemotactic and bactericidal capacity of gran‐
ulocytes and monocytes and inhibits the activity of natural killer cells and macrophages [35,
52]. A number of studies have demonstrated the adverse impact of IO on the development
infections in HSCT recipients. Tachibana et al observed an association between IO and blood
stream infections (BSI) in 114 patients who underwent allo–HSCT. They found that pre–
transplant serum ferritin levels significantly predicted BSI within the 100–day period after
allo–HSCT [1]. A direct correlation between hepatic IO and BSI was demonstrated in a retro‐
spective cohort of 154 allo – HSCT recipients, as patients with hepatic IO tended to experi‐
ence more frequent and prolonged episodes of lethal BSI [53]. Altes et al reported a ferritin
level above 1500 μg/l was associated with the occurence of bacteremia and febrile days in
first 3 months after auto–HSCT [27]. A prospective study investigated the risk factors for 140
early infection episodes which occured in 367 multiple myeloma (MM) patients undergoing
auto–HSCT. Bone marrow iron stores were identified as significant risk factors for early se‐
vere infections [54]. Pre–transplant serum ferritin levels were demonstrated to be associated
with fungal infections after allo–HSCT in several studies [33-35, 49, 55, 56]. Tunçcan et al
identified the predictive role of pre–transplant serum ferritin level in the development of
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hepatosplenic candidiasis among 255 HSCT recipients. Hepatosplenic candidiasis was diag‐
nosed in 6 (2, 3%) patients. Pre–transplant serum ferritin levels were significantly higher in
patients with hepatosplenic candidiasis [55]. Özyilmaz et al studied the relationship be‐
tween serum ferritin level and pulmonary fungal infections in 148 allo – HSCT recipients. In
this study, the sensitivity and specifity of ferritin > 1000 ng/ml for the prediction of fungal
pulmonary infections were found to be 67% and 70%, respectively [56].
2.3.4. Idiopathic Pneumonia Syndrome (IPS)
Idiopathic pneumonia syndrome comprises a group of disorders that result in interstitial
pneumonitis and/or widespread alveolar injury with an incidence of 2–8 % and a mortality
of up to 70% in the HSCT setting. There is increasing evidence implicating ROS and pro–
inflammatory events as major contributing factors to IPS [5, 24]. The mechanism of iron in‐
duced IPS probably involves endothelial injury by catalytically active iron released from
heme groups, which can trigger a cascade of events leading to acute lung injury and pulmo‐
nary fibrosis [24]. Currently, there are no studies regarding the direct association of IO and
IPS, except the oxidative milieu, which is partly a consequence of IO.
2.3.5. Graft-versus-host disease (GVHD)
The role of IO in the pathogenesis of GVHD has been evaluated in a number of studies.
There are conflicting results regarding the relationship between IO and GVHD in HSCT
recipients. In a prospective cohort of 190 allo – HSCT recipients reported by Pullarkat et
al, the effect of elevated pre–transplant ferritin on acute GVHD was assessed. Grade 2 or
above acute GVHD was diagnosed in 48% of patients.  Acute GVHD was more frequent
in  patients  with  high  ferritin  levels  (≥1000  ng/ml).  This  was  attributed  to  the  increased
ROS  mediated  injury  on  exposure  to  the  conditioning  regimen  in  iron  overloaded  pa‐
tients,  as  antigen  exposition  following  tissue  injury  was  indicated  to  be  the  initiating
event in the pathogenesis of GVHD [38]. Similarly in a report by Platzbecker et al, which
was performed in 172 patients with MDS, transfusion burden reflected by ferritin levels,
was found to be correlated with a higher probability of acute GVHD [57].  On the other
hand, Mahindra et al investigated 222 patients who underwent myeloablative allo–HSCT
and  demonstrated  that  pre–transplant  ferritin  level  >1910  μg/l  was  associated  with  de‐
creased  incidence  of  chronic  GVHD  [58].  Furthermore,  in  a  study  of  264  patients  who
underwent  allo–HSCT  for  various  hematological  malignancies,  no  significant  difference
in the cumulative incidence of acute and chronic GVHD was demonstrated in high (≥599
ng/ml) and low (<599 ng/ml) ferritin groups [59].  Alessandrino et al reported that trans‐
fusion dependency was an independent risk factor for the development of acute GVHD,
but not  for chronic GVHD [60].  On the other hand, IO might as well  mimic GVHD re‐
sulting in unnecessary continuation or intensification of  immunosuppressive therapy for
GVHD  [18].  Apart  from  hepatocellular,  cardiac  and  other  organ  dysfunction,  IO  may
worsen the natural course of liver GVHD, similar to the status with chronic hepatitis and
its response to therapy [3, 18, 23, 51, 57]. It is speculated that intestinal iron absorbtion is
increased as  a  result  of  epithelial  injury related to  chemotherapy or  GVHD. Suggesting
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that  IO might  be the consequence rather  than being the cause of  intestinal  GVHD [23].
The liver and the intestinal mucosa, which express essential iron regulatory genes includ‐
ing hepatic antimicrobial protein (HAMP), the gene that encodes hepcidin and ferropor‐
tin  1,  are  targets  of  conditioning  related  toxicity  as  well  as  GVHD,  initiated  by  donor
derived T  lymphocytes.  The  ensuing  release  of  cytokines  including  IL-6,  might  directly
affect the expression of hepcidin as IL-6 is a potent inducer of hepcidin via STAT3 [61].
Graft versus host disease also involves the interaction of Fas ligand expressed on activat‐
ed donor T lymphocytes with host tissue including enterocytes and hepatocytes.  T lym‐
phocyte  induced  tissue  damage  disrupts  iron  homeostasis  leading  to  uncontrolled  iron
accumulation which may aggravate tissue damage related to the development of GVHD
and infections [15]. The pattern of the relationship between IO and GVHD remains to be
confirmed in future studies.
2.4. Prognostic role of iron overload in stem cell transplantation
Several recent reports demonstrated that IO is an adverse prognostic factor for patients un‐
dergoing allo–HSCT [1, 17, 22, 36, 59, 62-66]. In a retrospective cohort of 114 AML and MDS
patients, the OS rate at 5 years was found to be significantly better in patients with ferritin
levels < 1000 ng/ml [1]. Tanaka et al evaluated the outcome of 47 patients with acute leuke‐
mia or MDS who underwent reduced intensity HSCT. High ferritin level which was defined
as >1000 ng/ml was associated with worse 2 year OS on multivariate analysis [62]. Another
study by the same group demonstrated the adverse impact of elevated ferritin levels on 5
year OS in a cohort of 143 patients with acute lymphoblastic leukemia (ALL) and acute mye‐
loblastic leukemia (AML) who received allo–HSCT with myeloablative and non myeloabla‐
tive conditioning regimens [63]. Transfusion dependency, predicted by serum ferritin levels,
was found to be independently associated with reduced OS and increased NRM in a retro‐
spective cohort of 357 MDS patients undergoing allo–HSCT [60]. The transplant iron score
which included serum ferritin level above 1000 ng/ml was tested in 78 patients who received
allo or auto–HSCT. The independent impact of IO on transplant survival was indicated with
the most pronounced predictive power of the iron score restricted to allo–HSCT recipients.
A high iron score (≥2) was associated with 50% absolute decrease in OS at 1 year [67]. Lim et
al reported the adverse impact of elevated serum ferritin on OS in 99 MDS patients who un‐
derwent reduced intensity HSCT [64]. Altes et al demonstrated that serum ferritin levels
≥3000 μg/l and TS ≥100% were associated with a decreased OS and increased TRM, which
was attributed to a high infectious mortality [32]. On the other hand Pullarkat et al analyzed
190 patients and demonstrated that elevated pre–transplant ferritin levels were associated
with increased risk of death and day 100 mortality, mainly due to acute GVHD and infec‐
tions [38]. Mahindra et al demonstrated a pre–transplant serum ferritin > 685 ng/ml was as‐
sociated with lower OS and relapse free survival in 315 patients with Hodgkin and non
Hodgkin lymphoma who received auto–HSCT, whereas same ferritin level exhibited a high‐
er incidence of relapse and relapse mortality. They identified the baseline ferritin level was
best correlated with poor survival. They concluded that elevated iron stores may also in‐
crease tumor growth, as tumor cells require more iron for DNA synthesis due to rapid pro‐
liferation [36]. Same group confirmed their results in a study of 222 allo–HSCT recipients
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with a serum ferritin level >1910 μg/l associated with lower OS, lower relapse free survival
and higher NRM rates [58]. Furthermore they demonstrated inferior survival rates related to
higher rates of TRM and relapse mortality in patients with elevated ferritin levels who re‐
ceived non myeloablative conditioning [37]. In a large retrospective study by Armand et al,
an elevated pre–transplant serum ferritin level was significantly associated with lower OS
and disease free survival. This association was particularly restricted to patients with acute
leukemia and MDS which was particularly attributed to transfusion load. They suggested a
possible role of iron chelation therapy in the pre and post – transplant setting, as they
showed an absolute difference of 37% in 5–year OS for patients with MDS between the high‐
est and lowest ferritin quartiles [66]. Sucak et al demonstrated an adverse impact of a pre–
transplant serum ferritin level >500 ng/ml on OS and TRM in 250 patients who received auto
and allo–HSCT, underscoring the prognostic effect of IO in auto transplants [49]. The same
group confirmed their results with a more toxic form of iron, NTBI, in a retrospective cohort
of 149 patients. In concordance with the previous report, a significant impact of NTBI on
day 30 and day 100 survival was shown in auto–transplanted patients for the first time in
iron and transplant connection [29]. Notwithstanding, in a prospective study by Armand et
al, pre–transplant IO predicted by LIC which is considered to be the gold standard indicator
of IO, was not found to be associated with increased mortality, relapse, SOS or GVHD [68].
Therefore, they assumed that the adverse prognostic impact of pre–transplant hyperferriti‐
nemia may be related to factors independent of IO. Taken together, it is speculated that fer‐
ritin may be prognostic not because it reflects iron stores but because it is an acute phase
reactant [68, 69].
2.5. Diagnosis of iron overload
2.5.1. Liver biopsy
Liver remains to be the most accessible parenchymal organ that can be used to estimate tis‐
sue iron load after HSCT. Iron overload is not uncommonly seen in various other primary
liver diseases such as alcoholic liver disease, chronic viral hepatitis, non alcoholic steatohe‐
patitis, liver cirrhosis and HH. Histological evaluation of liver specimens is essential in the
management of these disorders. The reported incidence of significant liver fibrosis in HSCT
recipients varies from 5% to 80% and LIC has been demonstrated to have a particular role in
the progression of fibrosis [26, 41, 70]. Though ferritin continues to be the mainstay for the
initial clinical evaluation of IO, liver biopsy is still the gold standard for quantifying iron.
Measurement of hepatic iron stores provides the most reliable estimate of body iron burden.
Liver iron content exceeding 80 mcmol/g of liver dry weight was found to be consistent with
IO with a hepatic index greater than 1, 9 mmol/kg/year. However, the need for a relatively
large volume of tissue as well as its invasive nature has made this procedure less appealing
to most clinicians and patients [4, 9, 53]. Although liver biopsy is an invasive procedure and
can not be safely administered in patients with very low platelet counts, a liver biopsy can
be advantageous in some HSCT recipients as it can also exclude alternative causes of hepatic
dysfunction, such as infections and GVHD. In high risk patients, liver biopsy using a trans‐
juguler approach may be a feasible alternative to percutaneous biopsy [4, 17].
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2.5.2. Non-invasive procedures
Superconducting quantum interference device (SQUID) assesses total body iron by using bi‐
omagnetic susceptometry. Ferritin and hemosiderin are the only paramagnetic materials in
the human body, thus the magnitude of these parameters is directly related to the amount of
iron in a certain volume of tissue. The device utilizes the magnetic property of iron in ferri‐
tin and hemosiderin to estimate hepatic iron stores. Furthermore, it is considered to be the
non invasive reference standard for estimation of LIC as it has an excellent correlation with
liver biopsy. However, widespread clinical use is limited by its cost, complexity and very
limited availability [4, 9, 17].
Liver iron content measurement has limited predictive value for extrahepatic iron deposi‐
tion. The liver is the dominant iron reservoir for the body, accounting for more than 80% of
the total body iron and has high capacity mechanisms for clearing both transferrin and NTBI
species from the circulation. The heart and endocrine tissues have tightly regulated transfer‐
rin uptake and develop IO only when there is circulating NTBI. High liver iron (15-20 mg/g
dry weight) damages liver parenchyma and increases circulating NTBI levels dramatically.
As no liver iron can be considered safe from a cardiac and endocrinological perspective, ex‐
trahepatic monitoring by magnetic resonance imaging (MRI) is essential [71]. Magnetic reso‐
nance imaging becomes increasingly important in the evaluation of iron status as it is non
invasive, more rapidly and widely available. Designating liver iron by older MRI techniques
and equipment showed variable correlation with the biopsy estimates of LIC. More recent
MRI techniques T2* and R2* MRI are reproducible methods for non invasive estimation of
LIC with reported sensitivity and specifity of 89% and 80%, respectively [4, 17, 72-74]. It has
the additional benefit of identifying relatively early IO within organs prior to the onset of
dysfunction. Magnetic resonance imaging can be used to co-measure iron deposition within
the heart, liver and pituitary gland as it does not appear that a single organ gives the full
picture of total body IO. In fact, patients can accumulate cardiac iron, despite apparently
normal hepatic iron levels and thus be at risk for arrhythmia or congestive heart failure. The
discordance of values in two tissues can be resolved with the use of MRI to detect cardiac
iron. Cardiovascular MRI could potentially be used not only to determine myocardial iron
content but also cardiac function and therefore could be used to investigate the effects of
iron mediated organ damage. Non invasive measurement of LIC has also been achieved us‐
ing an MRI technique based on the proton transverse relaxation rates within the liver. The
technique can be implemented on, most clinical 1, 5–T MRI measurements, making it readily
available to the clinical community. This technique resulted in a high specifity and sensitivi‐
ty over a greater range of LIC than any other MRI–based method of LIC assessment [9].
2.5.3. Ferritin
High prevalence of IO in long term survivors of HSCT emphasizes the need for routine
screening for IO in this population. Ferritin is a cellular iron storage protein that buffers
iron in a  soluble and non toxic  form. Under normal conditions ferritin levels  in the se‐
rum  are  low  but  steadily  increase  in  conditions  of  IO.  Therefore,  assessment  of  serum
ferritin levels serves as a simple and widely used surrogate marker for IO. Serum ferri‐
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tin levels are however subject to natural fluctuation and can also be greatly affected by a
range  of  inflammatory  conditions  that  are  particularly  relevant  in  HSCT recipients.  Al‐
though being a useful test for initial screening of IO in HSCT recipients, serum ferritin is
not a reliable indicator of total body iron burden particularly in patients who have ongo‐
ing acute infections or inflammatory diseases [2, 4, 17, 20, 22, 23, 38, 75, 76]. Serial serum
ferritin  measurements  can compensate  the  potential  fluctuations  and help to  establish a
general  picture  of  IO  over  time.  Nevertheless,  at  1  year  after–transplantation  when  in‐
flammatory  stress  has  largely  subsided,  most  patients  have  a  serum  ferritin  of  <1000
ng/ml and no clinical evidence of IO; serum ferritin in these patients decline slowly with
time [23].  Unlike tissue ferritin a substantial  proportion of serum ferritin is glycosylated
which  suggests  that  plasma ferritin  is  actively  secreted  from  reticuloendothelial  system
or  parencymal  cells.  Serum ferritin  in  contrast  to  tissue  ferritin  was  claimed to  have  a
low  iron  content  even  in  iron  loaded  patients  in  some  earlier  studies.  It  is  therefore
claimed that serum ferritin does not provide a major source of hepatic iron either in nor‐
mal individuals or in patients with IO diseases [4,  20,  22,  23,  75].  On the contrary a di‐
rect correlation between serum ferritin levels and transfusion burden has been observed
with a level of 1000 ng/ml after a median of 21 PRBC transfusions. Thus repeated meas‐
urement of serum ferritin levels seems to be a valid method to monitor secondary IO in
patients  with  transfusion  dependent  anemias  and  MDS  [17].  Majhail  et  al  studied  the
prevalence of IO in 56 allo–HSCT recipients and demonstrated the poor predictive value
of  ferritin  for  estimating  LIC.  The  overall  prevalence  of  IO was  32%.  Clinically  signifi‐
cant  IO  (LIC>7  mg/g)  was  uncommon  in  patients  with  serum  ferritin  levels  less  than
1000 ng/ml. However, the LIC on MRI was moderately correlated with serum ferritin. As
a result, they indicated ferritin to be a good screening test but a poor predictor of tissue
IO and recommended estimation of LIC before initiating chelation therapy. They consid‐
ered that this lack of association between ferritin and LIC might be related to the varia‐
bility  in  ferritin  levels  because  of  ineffective  erythropoiesis  or  underlying  inflammation
or  infection  [20].  Whereas  in  a  study  by  Bazuave  et  al,  serum  ferritin,  transferrin,  TS,
iron, soluble transferrin receptor (sTfR) and C reactive protein levels in 230 HSCT recipi‐
ents were measured.  All  iron parameters were found to be significantly associated with
survival.  A  combination  of  ferritin  and  TS  was  shown  to  have  the  highest  prognostic
power. They concluded that the predictive power of ferritin was derived from its associ‐
ation with IO rather than inflammation. Inferior survival in patients with IO was related
to both TRM and relapse. As sTfR and TS were found to have superior prognostic value
when compared to ferritin, they suggested to combine serum ferritin with TS for predic‐
tion of IO [2].
Recent evidence suggests that the determination of iron status before HSCT has important
prognostic implications. There is a gap between the time that patients are identified for
HSCT and the time that actual transplant takes place. During this period, most patients stay
transfusion dependent. After patients are exposed to conditioning regimen and stem cell in‐
fusion, serum ferritin levels are prone to a false elevation due to its role as an acute phase
reactant. Thus, accurate evaluation and diagnosis of iron toxicity after HSCT remains as a
challenge [53, 67] [Table 3].
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Diagnostic Test Advantages Disadvantages
Liver Biopsy Reference method, can assess degree of
hepatic fibrosis, can evaluate other causes of
hepatic dysfunction (GVHD)
Invasive procedure, not feasible in patients with
thrombocytopenia or coagulopathy
SQUID Good correlation with liver biopsy,
noninvasive
Very limited availability
MRI Good correlation with liver biopsy (T2 or R2
MRI), noninvasive, widely available
Variety of MRI techniqueshave not been validated




Noninvasive, widely available Sensitive but not specific for IO, poor correlation
with liver biopsy
Table 3. Diagnostic Tests for Assessment of Body Iron Stores in HSCT Recipients [4]
2.5.4. Non Transferrin Bound Iron (NTBI)
Non transferrin bound iron is toxic to living systems because it can act as a catalyst in the
formation of ROS which in turn stimulate lipid peroxidation in membranes. In iron-over‐
loaded states when SIBC becomes fully saturated, NTBI complexes appear in the serum. In a
study by Harrison et al, serum ferritin was raised in 21 of 28 patients following treatment for
hematological malignancy, whereas only 16% of them had LFT abnormalities. However,
NTBI was detected in 4 of 6 patients with an unexplained elevated LFTs. Therefore, they
considered that NTBI might be a more specific indicator of IO than the serum ferritin con‐
centrations [77]. Assessment of NTBI is a potentially useful approach that allows the estima‐
tion of toxic iron levels. However, the methods for determining this free fraction of body
iron and its precise prognostic significance require fine tuning [17].
2.6. Treatment of iron overload
The current paradigm of managing post–transplant IO is based on extensive experience in
children with transfusion dependent anemias [4]. Post–transplant iron depletion therapy has
been shown to reverse hepatic fibrosis and cardiomyopathy in patients with thalassemia [4,
78]. However, there is no published data indicating the benefit of iron removal therapy on
long term morbidity and mortality in HSCT recipients, especially for diseases other than
thalassemia [4].
Decisions regarding the management of IO should be individualized and based on a review
of several factors including the need for ongoing PRBC transfusion therapy, time since
transplantation, ability to tolerate iron depleting therapy and urgency to reduce body iron
stores [Table 4]. For instance, coexisting anemia can preclude the use of phlebotomy where‐
as renal impairment might increase the risk of toxicity from iron chelating drugs. Also de‐
pletion of iron stores would be more imperative in patients with IO related liver test
abnormalities or cardiac dysfunction compared to those without end organ toxicites [4].




Phlebotomy Extensive experience with proven efficacy,
no significant side effects
Not feasible in patients with anemia or poor venous
access
Deferoxamine Extensive experience with proven efficacy Inconvenient administration route and schedule,
side effects (ototoxicity, growth retardation)
Deferiprone Oral iron chelator Unproven efficacy, side effects (neutropenia,
hepatic fibrosis)
Deferasirox Oral iron chelator, efficacy similar to
deferoxamine
Long term toxicity profile not established, side
effects (nephrotoxicity)
Table 4. Treatment Options for Iron Overload after HSCT [4]
Iron overload may be a cause of persistent hepatic dysfunction after HSCT. Patients with
LIC>15 mg/g dry weight should be treated aggresively with both phlebotomy and chelation;
when LIC is 7–15 mg/g dry weight, phlebotomy is indicated; when LIC is under 7 mg/g dry
weight treatment is indicated only if there is evidence of liver disease. Mobilization of iron
from heavily overloaded patients improves cardiac function, normalizes serum alanine
transaminase levels and results in improved liver histology [24, 79].
In patients with extreme IO, effective pre–transplant chelation therapy is suggested to im‐
prove post–transplant survival, as IO is clearly related to treatment related morbidity and
mortality after HSCT [4, 24, 67, 79]. In the pre–transplant period vigorous iron chelation may
be important but prospective studies are required to prove a survival benefit after HSCT. In
the post–transplant period phlebotomy sometimes combined with erythropoiesis stimulat‐
ing agents (ESA) may be successfully applied in thalassemia. For those patients who can not
be phlebotomized iron chelation can be considered. Prospective studies of the impact of iron
chelation therapy before and after HSCT on post–transplant morbidity and mortality are
mandatory [4, 24].
The American Society for Blood and Marrow Transplantation (ASBMT) 2012 guidelines rec‐
ommend annual serum ferritin measurement in patients who received PRBC transfusions
pre or post–transplantation. Subsequent monitoring with serum ferritin should be consid‐
ered among patients with elevated levels, especially in the presence of abnormal LFTs,
PRBC transfusions or HCV infection. Additional diagnosting testing including liver biopsy,
MRI or SQUID may be indicated if therapy is intended for presumptive IO. Current pre‐
scribing guidelines recommend continuation of iron reduction till ferritin levels are below
500 ng/ml [3, 9, 51, 60, 72].
2.6.1. Phlebotomy
Phlebotomy is a feasible option for the treatment of IO following HSCT. Many studies have
documented its efficacy in early and late post–transplant setting. It has been shown that sub‐
clinical left ventricular diastolic dysfunction and impaired left ventricular contractility in pa‐
tients with thalassemia may be reversed by phlebotomy initiated after HSCT [51]. Iron
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overload should be treated by means of phlebotomy and/or chelation therapy especially
when IO coexists with chronic viral hepatitis. Phlebotomy has the advantage over chelation
of better compliance, fewer side effects and lower costs. The use of ESA may facilitate the
success of this strategy in patients with low hemoglobin levels [4, 19, 22, 26, 70].
After normalization of transaminases and serum ferritin with aggressive phlebotomy, main‐
tenance phlebotomy is required every 3-6 months to prevent iron reaccumulation and keep
serum ferritin in a low normal range. The gradual rise in ferritin after successful iron deple‐
tion suggests that there is a signal for increased iron absorbtion and the signal persists well
beyond the peri–transplant period. It may be that post–transplant immunosuppressants re‐
duce the level of cytokines that normally stimulate hepcidin production and allow increased
absorbtion of dietary iron. In addition hepatic GVHD may result in disordered hepcidin reg‐
ulation, as it likely does in chronic viral hepatitis and might explain increased risk of IO and
the need for maintenance phlebotomy after successful iron depletion [23].
2.6.2. Iron chelation
Treatment with phlebotomy is not possible in patients who are transfusion dependent. Che‐
lation may be preferred for iron depletion [9]. There are limited data on the pharmacological
chelation of iron during the post–transplant period including the safety, optimal dose, time
for initiation of treatment and duration of therapy [51, 80, 81].
Deferoxamine, the first available iron chelator, has a proven efficacy and safety with dec‐
ades  of  experience  and has  also  been  studied in  HSCT recipients.  Recommended treat‐
ment schedule is at least 5 nights per week subcutaneous delivered via a pump for 8-12
hours [4,  9].  It  is effective in lowering serum ferritin levels and LIC and prevents endo‐
crinological  complications.  Long  term  treatment  is  also  associated  with  a  reduction  in
cardiac complications and improved survival. Redness and induration at the infusion site
are the most common side effects. Audiological, ophthalmological, growth and bone tox‐
icities  may  be  minimized  by  avoiding  overchelation.  Deferoxamine  treatment  in  the
HSCT setting is complicated by the short half life and the ability to release iron to bacte‐
ria and fungi. Deferoxamine supports the growth of zygomycetes because it acts as xeno‐
sidephore  delivering  iron  to  iron  uptaking  molecules  of  the  species  [22,  51,  81].  The
greatest challenge with DFO is patient adherence with therapy because the need for pa‐
renteral administration is cumbersome, uncomfortable, inconvenient and time consuming
[51].  Cardiac  morbidity  and  mortality  continue  to  occur  in  patients  treated  with  DFO,
likely related to difficulties with adherence [4, 9, 22, 51, 81].
Deferiprone is an oral iron chelator which was first identified in 1980s and subsequently ap‐
proved for clinical use in Canada and Europe especially when DFO is contraindicated. Deferi‐
prone is not commercially available in all countries and has not been investigated in HSCT
recipients. It has a short half life of only 1, 5 hours and thus requires 3 times daily dosing. Un‐
fortunately, it does not control liver iron as effective as DFO even after years of continued treat‐
ment.  In contrast,  a recent study in patients with thalassemia showed better myocardial
function in those receiving Deferiprone. Retrospective studies have also demonstrated re‐
duced cardiac morbidity and mortality and lower myocardial iron deposition among patients
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treated with Deferiprone compared with DFO and Deferasirox (DFX). A reduction or stabiliza‐
tion of serum ferritin levels and LIC in most patients with transfusional IO was demonstrated.
The high risk of agranulocytosis necessitates weekly blood monitoring. Thus, toxicity profile of
the drug may be inappropriate for transplant recipients [4, 9, 81].
A novel oral iron chelator, DFX was approved by the US Food and Drug Administration in
2005 and represents a significant advancement in the treatment of IO. It is a tridentate oral iron
chelator which is lipid soluble but highly protein bound. It has a plasma half life about 12 hours
and thus is ideal for once daily dosing. It binds iron in a 2/1 ratio. It is excreted by the hepatobili‐
ary system and the chelated iron is excreted via the feces. The effective dose is between 20-40
mg/kg. It is generally well tolerated by patients although some dose modifications may be nec‐
essary for diarrhea. Phase III trials demonstrated that DFX at 20-30 mg/kg/day led to the main‐
tenance or reduction of iron burden as measured by LIC in chronically transfused patients.
Reductions in LIC and serum ferritin are similar to those found in the subcutaneous use of
DFO. Commonly reported side effects include skin rash, nausea, vomiting and diarrhea and el‐
evations in serum creatinine levels, which may be important in patients treated with calcineur‐
in inhibitors. Gastrointestinal disturbances often improve with continued administration of
the drug. Elevations in serum creatinine occur in approximately 1/3 of subjects. Side effects as‐
sociated with DFX therapy may overlap or exacerbate early complications such as calcineurin
induced renal injury seen after allo–HSCT, which Mkes it complicated to use early after HSCT.
The availability of an oral iron chelator has simplified the treatment of IO, but more experience
with its use in HSCT recipients is needed [4, 9, 22, 80, 81].
3. Conclusion
The role of IO in HSCT recipients and guidelines for screening strategies warrants further stud‐
ies. The value of routine screening for IO, the method of determining it, whether it should be
with serum ferritin, by determining LIC with non invasive MRI or biopsy and identifying a sub‐
group of patients who might benefit from phlebotomy and/or iron chelating agents requires fu‐
ture prospective studies.  The possibility of IO should be considered in patients who are
candidates for HSCT. Red blood cell transfusion should be limited whenever possible and chela‐
tion and/or phlebothomy should be considered in the course of documented IO. pre–transplant
preventive measures should also be adopted to avoid IO and improve survival in these patients.
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